Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Eric Kristiansen • October 14, 2021

Female-led women’s health companies announce comprehensive partnership designed to empower breast cancer community

ALISO VIEJO, Calif. & PROVIDENCE, R.I.--(BUSINESS WIRE)--Brilliantly and Mammogen, Inc., two female-led women’s health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physician’s office.


The collaboration, which will equip breast cancer previvors and survivors with the tools they need to live empowered lives, is an intentional step towards each company’s commitment to advancing every aspect of women’s health, beyond traditional product-related decisions.


“Over my nearly twenty years in the diagnostics industry, it has always baffled me that companies never invest time or resources to empower the communities that they serve,” said Elizabeth Cormier-May, CEO of Mammogen. “Whether you’re at a higher risk of developing breast cancer based on genetics or family history, newly diagnosed, or past your five-year mark, there’s no shortage of mental, emotional and physical anguish associated with this disease. At Mammogen, we work tirelessly to innovate around the clinical and the personal experience, not only because it makes great business sense; but, most importantly, because it is the right thing to do. We know that end-to-end care is good but creating an end-to-never-end community is far more powerful, and our partnership with Brilliantly brings us a step closer to fulfilling that mission.”


The comprehensive collaboration will first include an exclusive book project which will be a collection of short stories, interviews and creative writing pieces representing hundreds of voices that address everything from talking about hereditary risk with children to sexual dysfunction to career changes.

“For many of us, the aftermath of surgical intervention and treatment has simply been called ‘the new normal’, yet it doesn’t feel normal at all,” stated Kristen Carbone, Founder and CEO of Brilliantly and breast cancer previvor. “How can we feel normal again? Where do we even start? The issues faced by this community are so multifaceted, I struggle to think of even a single part of everyday life that isn’t impacted in some way by an experience with breast cancer,” continued Carbone.


The second initiative is a corrective exercise program that will include various workout modalities to help regain strength and mobility safely for women who’ve had breast surgery and/or treatment. Specific exercise routines for breast cancer patients, survivors, and previvors have been proven to improve quality of life as well as decrease mortality.1 This collaboration between Mammogen and Brilliantly will ensure that all women have access to appropriate exercise routines throughout their journeys.


Both initiatives, while currently underway, will officially kick off in early 2022, upon successfully securing necessary sponsorship.

About Mammogen

Mammogen is a female-led biotechnology company focused on meaningfully improving the detection, diagnosis and treatment of women’s health-related diseases, and creating an end-to-never-end community for women around the world. Mammogen is centered around its proprietary genTRUTM liquid biopsy platform. The company’s flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer. The genTRUTM offering is positioned to unlock regular and reliable screening for millions of women around the world and eliminate many negative, invasive biopsy procedures. The company’s proprietary multi-gene expression signature for breast cancer detection has been extensively validated in blood, as well as saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. Mammogen’s product pipeline consists of an array of non-invasive prognostics and diagnostics for additional diseases that affect some-, mostly-, or only-women. For more information visit www.mammogen.bio.

About Brilliantly

Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services. The company has recently released their flagship technology, Brilliantly Warm, the first-ever wearable designed specifically for women who have had breast reconstruction surgery. For more information visit www.brilliantly.co.


  1. JNCI J Natl Cancer Inst, 2021, Vol. 113, No. 1
November 3, 2026
November 3, 2026 | In the News | Forbes Mammogen has been featured in Forbes in an article by Geri Stengel exploring the company's mission to transform breast cancer detection through innovative RNA-based blood testing. The feature highlights Mammogen's co-founder and CEO, Elizabeth Cormier-May, and her vision for making earlier breast cancer detection more accessible, particularly for women with dense breast tissue. At the center of the story is genTRU-breast™ , Mammogen's investigational blood-based diagnostic designed to complement existing breast imaging and provide additional biological insights that may help inform clinical decisions. The Forbes article also explores Mammogen's Series A financing of up to $30 million, its approach to affordability and patient access, and its ongoing commitment to prospective clinical validation. A major focus is the KATELYN-ERIN clinical study, designed to enroll approximately 2,600 women to further evaluate the performance of genTRU-breast™. As Mammogen continues advancing its technology toward clinical integration, the Forbes feature brings attention to an important challenge in women's health: improving access to meaningful information that can support earlier detection and more informed care. Read the full Forbes feature: Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test Originally published by Forbes on November 3, 2026. Written by Geri Stengel. This summary was independently prepared by Mammogen. genTRU-breast™ is under clinical development, and prospective validation is ongoing.
Show More
November 3, 2026
November 3, 2026 | In the News | Forbes Mammogen has been featured in Forbes in an article by Geri Stengel exploring the company's mission to transform breast cancer detection through innovative RNA-based blood testing. The feature highlights Mammogen's co-founder and CEO, Elizabeth Cormier-May, and her vision for making earlier breast cancer detection more accessible, particularly for women with dense breast tissue. At the center of the story is genTRU-breast™ , Mammogen's investigational blood-based diagnostic designed to complement existing breast imaging and provide additional biological insights that may help inform clinical decisions. The Forbes article also explores Mammogen's Series A financing of up to $30 million, its approach to affordability and patient access, and its ongoing commitment to prospective clinical validation. A major focus is the KATELYN-ERIN clinical study, designed to enroll approximately 2,600 women to further evaluate the performance of genTRU-breast™. As Mammogen continues advancing its technology toward clinical integration, the Forbes feature brings attention to an important challenge in women's health: improving access to meaningful information that can support earlier detection and more informed care. Read the full Forbes feature: Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test Originally published by Forbes on November 3, 2026. Written by Geri Stengel. This summary was independently prepared by Mammogen. genTRU-breast™ is under clinical development, and prospective validation is ongoing.
October 9, 2026
Rockford News First | October 9, 2026
June 30, 2025
Renowned global builder of boards and executive teams aligns with leading women's health innovator, signaling next phase of commercial growth
December 2, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
December 2, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
November 16, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
By Eric Kristiansen • June 4, 2023
IVBH's novel RNA approach to early detection demonstrates strong sensitivity and specificity for early lung cancer detection, in a large, predominantly early-stage, independent validation cohort